Role of the Bone Marrow Microenvironment in Drug Resistance of Hematological Malignances.


Journal

Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157

Informations de publication

Date de publication:
2022
Historique:
received: 15 03 2021
revised: 07 07 2021
accepted: 20 07 2021
pubmed: 14 9 2021
medline: 18 5 2022
entrez: 13 9 2021
Statut: ppublish

Résumé

The unique features of the tumor microenvironment (TME) govern the biological properties of many cancers, including hematological malignancies. TME factors can trigger an invasion and protect against drug cytotoxicity by inhibiting apoptosis and activating specific signaling pathways (e.g. NF-ΚB). TME remodeling is facilitated due to the high self-renewal ability of the bone marrow. Progressing tumor cells can alter some extracellular matrix (ECM) components which act as a barrier to drug penetration in the TME. The initial progression of the cell cycle is controlled by the MAPK pathway (Raf/MEK/ERK) and Hippo pathway, while the final phase is regulated by the PI3K/Akt /mTOR and WNT pathways. This review summarizes the main signaling pathways involved in drug resistance (DR) and some mechanisms by which DR can occur in the bone marrow. The relationship between autophagy, endoplasmic reticulum stress, and cellular signaling pathways in DR and apoptosis is covered in the TME.

Identifiants

pubmed: 34514979
pii: CMC-EPUB-117861
doi: 10.2174/0929867328666210910124319
doi:

Substances chimiques

Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2290-2305

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Alireza Hosseini (A)

Laboratory Hematology and Blood Banking, Tehran University of Medical Sciences, Tehran, Iran.

Michael R Hamblin (MR)

Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa.

Hamed Mirzaei (H)

Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.
Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran.

Hamid R Mirzaei (HR)

Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran. Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH